Responses
Featured Posters: Poster Rounds with the Professors
AS11. Ovarian cancer
PR062/#686 First-in-human phase 1 study of torl-1–23, a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) in patients with ovarian cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.